{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013654","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.264970+00:00","generated_at":"2026-05-15T08:22:03.378640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026","bullets":["Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.","Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.","R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.","Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.","Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013654","json":"https://secwatch.observer/filing/0001493152-26-013654.json","markdown":"https://secwatch.observer/filing/0001493152-26-013654.md","text":"https://secwatch.observer/filing/0001493152-26-013654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/0001493152-26-013654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:22:03.378640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2beb5016b38466d840be9f863f49ebb4a08dec10","claim":"Glucotrack, Inc. reported full year ended December 31, 2025 results: net income Net loss for the full year 2025 was $19.4 million.","evidence_excerpt":"Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/0001493152-26-013654-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the full year 2025 was $19.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}